![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » MOMENTA PHARMACEUTICALS AND SANDOZ SIGN EXCLUSIVE COLLABORATION TO DEVELOP COMPLEX GENERICS AND FOLLOW-ON VERSIONS OF BIOTECHNOLOGY DRUGS
MOMENTA PHARMACEUTICALS AND SANDOZ SIGN EXCLUSIVE COLLABORATION TO DEVELOP COMPLEX GENERICS AND FOLLOW-ON VERSIONS OF BIOTECHNOLOGY DRUGS
July 25, 2006
Momenta Pharmaceuticals, Inc.,a biotechnology company specializing in the characterization and engineering of complex drugs, announced an exclusive collaboration with Sandoz, the generics business of Novartis, to develop four follow-on and complex generic versions of previously approved recombinant biotechnology and complex drugs.
Biotech
Intelligence
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct